Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIC-E: Experimental Drugs for COVID-19
NCT04393246Phase 3Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of EDP1815, dapagliflozin, ambrisentan in coronavirus disease 2019 (COVID-19), sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Jul 2020; status: completed.
02
Drugs
EDP1815dapagliflozinambrisentan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04393246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393246.